These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 24167634)

  • 21. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
    Wang J; Wei H; Zhao B; Li M; Lv W; Lv L; Song B; Lv S
    J Mol Histol; 2014 Dec; 45(6):641-52. PubMed ID: 25008024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
    Feng W; Xie Q; Liu S; Ji Y; Li C; Wang C; Jin L
    Cancer Sci; 2018 Jun; 109(6):1775-1786. PubMed ID: 29624806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
    Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
    PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition.
    Zhou FM; Wang KK; Wang LH; Qiu JG; Wang W; Liu WJ; Wang L; Jiang BH
    Aging (Albany NY); 2024 Sep; 16(17):12277-12292. PubMed ID: 39264588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
    Chung JH; Rho JK; Xu X; Lee JS; Yoon HI; Lee CT; Choi YJ; Kim HR; Kim CH; Lee JC
    Lung Cancer; 2011 Aug; 73(2):176-82. PubMed ID: 21168239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.
    Lu Y; Liu Y; Oeck S; Glazer PM
    Mol Cancer Res; 2018 Oct; 16(10):1458-1469. PubMed ID: 29934325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
    Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
    Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
    Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
    Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
    J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.